Semaglutide: Reference Overview and Reconstitution Notes

July 9, 2026

Semaglutide

What it is

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, a modified peptide based on the naturally occurring incretin hormone GLP-1. It is structurally engineered for a longer duration of action than native GLP-1, which is why it is commonly discussed as a once-weekly injectable or oral formulation in the literature.

Research context and categorization

Semaglutide is grouped under the metabolic and weight-regulation category. Mechanistically it is discussed in relation to GLP-1 receptor signaling, which is studied in the context of blood-glucose regulation, insulin release, gastric emptying, and appetite or satiety signaling.

Beyond its approved metabolic uses, semaglutide is the subject of active investigational research. It has been studied in the context of cardiovascular and kidney outcomes, and it is being investigated for its effects in non-alcoholic steatohepatitis (NASH). A growing body of work also examines GLP-1 receptor agonists in relation to addiction and craving, including trials on alcohol use disorder, and it is discussed in relation to neuroprotection and neurodegenerative conditions because GLP-1 receptors are present on multiple brain cell types. These broader uses are exploratory and are not confirmed or approved outcomes.

Status

Regulatory status: FDA-approved for specific indications, including glycemic control in type 2 diabetes, chronic weight management, and reduction of certain cardiovascular and kidney risks, marketed under brand names such as Ozempic, Wegovy, and Rybelsus.
Sport status: Not specifically listed as prohibited on the 2026 WADA Prohibited List. However, semaglutide (along with tirzepatide) was added to the WADA Monitoring Program effective January 1, 2026, meaning its markers are being surveilled in and out of competition to observe possible misuse. Monitoring is surveillance rather than a ban, and its status could change in future List cycles.

Reconstitution notes (general)

For lyophilized (freeze-dried) peptides supplied as a powder, the working concentration is determined by a simple relationship: concentration equals the milligrams of peptide in the vial divided by the millilitres of bacteriostatic water added. For example, 5 mg of powder reconstituted with 2 mL of bacteriostatic water gives 2.5 mg/mL. To calculate a target concentration or water volume, see the calculator at /pages/tools.

Dilution and handling notes (compound-specific)

Semaglutide is often supplied for research as a lyophilized powder in vial sizes such as 5 mg and 10 mg. Typical reconstitution ranges cluster around a 5 mg vial mixed with roughly 2 mL to 2.5 mL of bacteriostatic water, yielding concentrations in the neighborhood of 2 mg/mL to 2.5 mg/mL; smaller 2 mg vials with 2 mL give about 1 mg/mL. Bacteriostatic water is generally preferred over plain sterile water because its benzyl alcohol preservative supports repeated withdrawals from a multi-use vial across the storage window.

Practical handling notes: semaglutide generally dissolves readily and clears within about a minute of gentle swirling, so it does not typically require the aggressive measures some harder-to-dissolve peptides need. It is prone to foaming if handled roughly, so the common technique is to run the water slowly down the inner wall of the vial rather than aiming the stream directly onto the powder cake, then swirl gently rather than shaking. Excessive agitation can stress the peptide and create foam that complicates accurate measurement. The reconstituted solution should be clear and colorless; cloudiness, particulates, or discoloration indicate it should be discarded. Note that oral tablet formulations of semaglutide are ready-to-use small-molecule-format products and are not reconstituted, so these notes apply only to lyophilized powder.

Handling and storage

Store the reconstituted solution refrigerated at 2 to 8 degrees Celsius, kept out of direct light. Wipe the stopper with an alcohol swab before each withdrawal, and label the vial with the mix date. A reconstituted solution is commonly treated as usable for roughly a four-week refrigerated window. Discard the solution if it becomes cloudy or discolored or if floaters or particulates appear.

Tools and supplies

For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.